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Although the virus yield reduction assay is a powerful technique for evaluating 
the efficacy of antiviral compounds, it is not routinely utilized due to its labor-in- 
tensive nature. This procedure was modified, developed, thereby reducing greatly 
the time and effort required to perform yield reduction assays. Monolayer cultures 
of mammalian cells were grown in %-well microtiter tissue culture plates and in- 
fected with virus. Test compounds were\ added and serially diluted directly with 
the plates. Following a cycle of virus replication, culture lysates were made and 
serially diluted in a separate set of uninfected cultures grown in microtiter plates. 
The cultures were incubated, plaques were enumerated in wells containing 5 to 20 
plaques, and virus titers were calculated. To illustrate the use of the assay the 
known antiviral drugs acyclovir and ganciclovir were evaluated using this proce- 
dure. Ninety percent inhibitory concentrations for the respective drugs were 3 PM 
and 0.7 FM against herpes simplex virus type 1 and 60 PM and 1 PM against hu- 
man cytomegalovirus. 
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Introduction 
A variety of different techniques currently are utilized in the evaluation of com- 
pounds for antiviral activity against herpesviruses. Some of the more frequently 
used procedures include plaque reduction (Plummer and Benyesh-Melnick, 1964; 
Wentworth and French, 1970), dye uptake (McLaren et al., 1983; Langlois et al., 
1986), nucleic acid hybridization (Gadler, 1983; Gadler et al., 1984), and enzyme- 
linked immunosorbent assays (Wahren et al., 1983; Rabalais et al., 1987). A less 
commonly used technique is the virus yield reduction assay (Shipman et al., 1976; 
Collins and Bauer, 1977). In this procedure virus-infected cultures are incubated 
with antiviral compounds for a period sufficient to permit virus replication and then 
assayed for the presence of new progeny virus by titration on separate monolayer 
cultures. Although this assay allows one to quantitate the production of infectious 
virions in drug-treated cultures, the labor-intensive nature of the assay thus far has 
precluded its widespread use as a routine technique. In an effort to simplify this 
assay we have modified it to take advantage of microtiter techniques. Herein we 
report a procedure for evaluating antiviral compounds against human cytomega- 
lovirus (HCMV) and herpes simplex virus type 1 (HSV-1) using a microtiter virus 
yield reduction assay. 
Materials and Methods 
Cells and viruses 
The routine growth and passage of primary human foreskin fibroblast (HFF) cells 
and an established line of African green monkey kidney (BS-C-1) cells and meth- 
ods for the propagation and titration of viruses have been described previously 
(Turk et al., 1987). The plaque-purified PO isolate of the Towne strain of HCMV 
was a gift of Dr Mark Stinski, University of Iowa, Iowa City, IA. The S-148 strain 
of HSV-1 was provided by Dr Thomas Schafer of Schering Corp., Bloomfield, NJ 
and was subcloned in our laboratory by limiting dilution (Klein, 1975). Homoge- 
neous virus stocks which exhibited small, uniform plaque morphology were used 
in this assay due to the small size of the tissue culture wells. 
HCMV yield reduction assay 
HFF cells were seeded into 96-well tissue culture plates at a concentration of 
12500 cells per well in 0.2 ml of minimal essential medium with Earle salts 
[MEM(E)] supplemented with 10% fetal bovine serum (FBS) and incubated at 37°C 
in a humidified 3% CO* - 97% air atmosphere. After 24 h plates were inverted 
over a waste vessel, medium was shaken out, and the plates were allowed to drain 
for 5 to 10 s on a sterile paper towel. Cultures were inoculated with HCMV at a 
multiplicity of infection (MOI) of 0.5 to 1 plaque forming units (PFU) per cell in 














Fig. 1. Pattern of drug addition to primary culture plate in the microtiter virus yield reduction assay. 
Monolayer cultures of mammalian cells were infected with virus and incubated for 2 h. Virus inocufum 
was removed and 0.2 ml fresh medium was added to each well. The top row of wells served as virus 
controls. To each well of the second row was added 0.1 ml of 300 pM test compound. The contents of 
the wells were mixed and serially diluted 1:3 down the plate by repeated transfer and mixing of 0.1 ml 
of drug-containing solution. Final drug concentrations obtained were 100, 33, 11, 3.7, 1.2, 0.41, and 
0.14 pM. 
pg streptomycin sulfate/ml using a microtiter multichannel pipette (Flow Labo- 
ratories, Inc., McLean, VA). Cultures were incubated at 37°C for 2 h to permit 
virus adsorption. Virus inoculum was replaced with 0.2 ml of fresh medium and 
test compounds were added to the cultures following the pattern illustrated in Fig. 
1. The first row of 12 wells was left undisturbed and served as virus controls. Each 
well in the second row received an additional 0.1 ml of MEM(E) containing 5% 
FIB, antibiotics, and test compound at three times the desired final concentration. 
The contents of the 12 wells were mixed by repeated pipetting and then serially 
diluted 1:3 down the plate by repeated transfer and mixing of 0.1 ml of drug-con- 
taining medium. In this manner, six compounds could be tested in duplicate on a 
single plate with concentrations ranging nearly lOOO-fold between the highest and 
lowest dilutions (0.14 PM to 100 PM, for example). Plates were incubated at 37°C 
for 7 days and then subjected to one cycle of freezing at -76°C and thawing at, 
37°C to disrupt the cells. Aliquots of 0.1 ml from each of the eight wells of a given 
column were transferred to the first column of a fresh 96-well monolayer culture 
of HFF cells. Contents were mixed and serially diluted 1:3 across the remaining 
11 columns of the secondary plate. Each column of the original primary plate was 
diluted across a separate plate in this manner. Cultures were incubated at 37°C for 
2 h to permit virus adsorption and then virus inoculum (containing residual test 
compounds carried over from the primary plate) was replaced with 0.2 ml of fresh 
medium. Cultures were incubated for 7 days, medium was removed, and the cell 
sheets were stained with 0.1% crystal violet in 20% methanol. Plaques were 
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enumerated under 20-fold magnification in the column of wells having the dilution 
which gave 5 to 20 plaques per well. Virus titers were calculated according to the 
following formula: Titer (PFU/ml) = number of plaques x 5 x 3”; where n rep- 
resents the n* dilution of the virus used to infect the well in which plaques were 
enumerated. 
HSV-1 yield reduction assay 
The procedure was essentially the same as for HCMV with the following mod- 
ifications: (i) BS-C-1 cells were used in place of HFF cells and were seeded at a 
concentration of 10000 cells per well in MEM(E) containing calf serum instead of 
FBS, (ii) cultures were inoculated with HSV-1 at an MO1 of five PFU per cell, (iii) 
the primary drug-treated cultures were incubated overnight rather than for 7 days, 
and (iv) secondary cultures were incubated for 2 days before staining. 
Results and Discussion 
The virus yield reduction assay is a powerful technique for evaluating the effi- 
cacy of potential antiviral compounds. It is a more stringent measure of the proc- 
ess of virus infection and drug activity than the plaque reduction assay because the 
MO1 is usually one or more PFU per cell as opposed to less than 0.01 PFU per 
cell in plaque reduction assays. In addition, the use of a higher MO1 and the quan- 
titation of progeny virus permits the determination of antiviral activity over a much 
greater range (l-106 PFU/ml in yield reduction compared to l-l@ PFU in plaque 
reduction), thereby permitting the measurement of more profound drug effects. 
The capacity of drugs to produce multiple IO-fold reductions in virus titer in vitro 
appears to correlate with in vivo drug efficacy. Despite these advantages, the virus 
yield reduction assay is not routinely utilized by many investigators due to its la- 
bor-intensive nature. 
In commonly reported versions of this assay (Cheng et al., 1983; Rasmussen et 
al., 1984; Turk et al., 1987; Snoeck et al., 1988) the primary drug-treated cultures 
are grown in 25 cm2 fIasks, petri dishes, or 24-well tissue culture plates. Culture 
lysates are prepared, diluted in test tubes, and virus titrated in 6-, 24, or 96-well 
plates. The use of microtiter techniques throughout the entire assay as reported 
herein simplifies this assay in a variety of ways, greatly reducing the handling re- 
quired. Six compounds can be assayed in duplicate using a total of only thirteen 
%-well culture plates. Test compounds are quickly and easily diluted directly in 
the wells of the plates. Similarly, culture lysates are diluted directly in the second- 
ary culture plates. Utilization of 1:3 dilutions across a 12-well row is sufficient to 
permit quantitation of up to lo6 PFU of virus per ml of a given cell lysate. In ex- 
periments in which higher virus titers are obtained, serial dilutions of the culture 
lysates may be extended across a portion of a second %-well plate. In contrast to 
procedures using culture plates with larger wells, no solid or semi-solid overlay 
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Fig. 2. Antiviral effect of acyclovir (0) and ganciclovir (m) on the replication of HSV-1 (panel A) and 
HCW (panel B) in the microtiter virus yield reduction assay. Each point represents the average of 
duplicate determinations. Control virus titers for HSV-1 and HCMV were 6.3 x I@ and 1.3 X 106 
plaque forming units per ml, respectively. 
microtiter plates. Lastly, the endpoint wells in which plaques’are enumerated typ- 
ically contain fewer than 20 plaques, greatly simplifying this counting step. 
To illustrate the utility of the microtiter yield reduction, assay we examined the 
antiviral activity of acyclovir (Burroughs Wellcome Co., Research Triangle Park, 
NC) and ganciclovir (Syntex, Palo Alto, CA) against both HSV-1 and HCMV. As 
illustrated in Pig. 2A, both compounds possess potent antiviral ,activity against HSV- 
1. Virus titers were reduced nearly X&fold in cultures treated' with 100 (LM of either 
compound. Ninety percent inhibitory concentrations of 0.7 FM and 3 PM can be 
interpolated from the dose-response curves for ganciclovir and acyclovir, respec- 
tively. Fig. 2B reveals that ganciclovir is a potent inhibitor of HCMV replication 
(>lti-fold reduction in virus titer at 100 PM) whereas acyclovir is lOOO-fold less 
active. Ninety percent inhibitory concentrations for the respective compounds are 
1 PM and 60 l.r.M. These results using the microtiter assay compare favorably with 
results reported by other investigators using their versions of the virus yield re- 
duction assay (Cheng et al., 1983; Rasmussen et al., 1984). In contrast, plaque re- 
duction assays for the two drugs do not adequately demonstrate their significant 
difference in activity against HCMV. For example, we have found in multiple ex- 
periments that the difference between 50 percent inhibitory concentrations for the 
two compounds was only 7- to g-fold (ganciclovir = 8.8 PM, acyclovir = 63 PM) 
(Pudlo et al., 1988), not 60- to lOOO-fold as revealed by yield reduction assay. 
In conclusion, we believe the virus yield reduction assay to be a more powerful 
and predictive technique than is the plaque reduction assay. Utilization of micro- 
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titer techniques has the benefit of reducing the time and amount of materials re- 
quired to perform the assay thereby providing a feasible method to routinely de- 
rive more meaningful results in the evaluation of antiviral compounds. 
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